IP Verse

Rna Containing Composition For Treatment Of Tumor Diseases - EP3326641

The patent EP3326641 was granted to Curevac on Jun 26, 2019. The application was originally filed on Apr 22, 2016 under application number EP17196250A. The patent is currently recorded with a legal status of "Revoked".

EP3326641

CUREVAC
Application Number
EP17196250A
Filing Date
Apr 22, 2016
Status
Revoked
Jun 27, 2024
Grant Date
Jun 26, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

FRIEDRICHApr 17, 2020FRIEDRICHWITHDRAWN
GRUNDMar 26, 2020GRUNDADMISSIBLE
PFIZERMar 26, 2020PFIZERADMISSIBLE
MERCK SHARP & DOHMEMar 24, 2020WICHMANNADMISSIBLE

Patent Citations (40) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP1083232
DESCRIPTIONUS7074596
DESCRIPTIONWO02098443
DESCRIPTIONWO03051401
DESCRIPTIONWO03086280
DESCRIPTIONWO2006008154
DESCRIPTIONWO2008016473
DESCRIPTIONWO2008077592
DESCRIPTIONWO2008083949
DESCRIPTIONWO2008157688
DESCRIPTIONWO2009030481
DESCRIPTIONWO2009149253
DESCRIPTIONWO2010037539
DESCRIPTIONWO2011015347
DESCRIPTIONWO2011026641
DESCRIPTIONWO2012013326
DESCRIPTIONWO2012019780
DESCRIPTIONWO2012113513
DESCRIPTIONWO2012116811
DESCRIPTIONWO2013059475
DESCRIPTIONWO2013143700
DESCRIPTIONWO2014127917
DESCRIPTIONWO2014189805
DESCRIPTIONWO9512673
DESCRIPTIONWO9521251
DESCRIPTIONWO9521915
OPPOSITIONEP2623121
OPPOSITIONWO02098443
OPPOSITIONWO2009095226
OPPOSITIONWO2011003883
OPPOSITIONWO2012013326
OPPOSITIONWO2012113513
OPPOSITIONWO2014127917
OPPOSITIONWO2017085228
SEARCHEP2623121
SEARCHWO02098443
SEARCHWO2006024518
SEARCHWO2009095226
SEARCHWO2012013326
SEARCHWO2014127917

Non-Patent Literature (NPL) Citations (88) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- Adv Drug Deliv Rev., (20140200), vol. 66, pages 110 - 116
DESCRIPTION- AKASHI, Curr. Opin. Genet. Dev., (20010000), vol. 11, no. 6, pages 660 - 666
DESCRIPTION- ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402
DESCRIPTION- ARDIANI et al., Curr. Gene Ther., (20120000), vol. 12, no. 2, pages 77 - 91
DESCRIPTION- ASHKENAZI, Nat. Rev. Drug Discov., (20080000), vol. 7, no. 12, pages 1001 - 1012
DESCRIPTION- BAUER S et al., Proc NatlAcadSci USA, (20010000), vol. 98, pages 9237 - 9342
DESCRIPTION- BERGER et al., Clin Cancer Res., (20080000), vol. 14, no. 10, pages 3044 - 3051
DESCRIPTION- BINDER et al., EMBO J., (19940000), vol. 13, pages 1969 - 1980
DESCRIPTION- BOUR-JORDAN et al., Immunol Rev., (20110000), vol. 241, no. 1, pages 180 - 205
DESCRIPTION- BRAHMER et al., J Clin Oncol., (20100000), vol. 28, no. 19, pages 3167 - 3175
DESCRIPTION- BRAHMER et al., N Engl J Med., (20120000), vol. 366, no. 26, pages 2455 - 2465
DESCRIPTION- BRINCKER, Crit. Rev. Oncol. Hematol., (19930000), vol. 15, no. 2, pages 91 - 98
DESCRIPTION- BRUNELLE et al., Methods Enzymol., (20130000), vol. 530, pages 101 - 114
DESCRIPTION- CAPUT et al., Proc. Natl. Acad. Sci. USA, (19860000), vol. 83, pages 1670 - 1674
DESCRIPTION- CELIKOGLU et al., Cancer Therapy, (20080000), vol. 6, pages 545 - 552
DESCRIPTION- ELMORE, Toxicol Pathol., (20070000), vol. 35, no. 4, pages 495 - 516
DESCRIPTION- FOLKMAN, N. Engl. J. Med., (19720000), vol. 285, no. 21, pages 1182 - 1186
DESCRIPTION- Front Pharmacol., (20151201), vol. 6, page 286
DESCRIPTION- GEALL et al., Semin. Immunol., (20130000), vol. 25, no. 2, pages 152 - 159
DESCRIPTION- GenBank, Database accession no. NM_000477.5
DESCRIPTION- GenBank, Database accession no. U26404
DESCRIPTION- GenBank, Database accession no. X65300
DESCRIPTION- GenBank, Database accession no. X65327
DESCRIPTION- GRANER MW; LILLEHEI KO; KATSANIS E, "Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines", Front Oncol., (20150106), vol. 4, page 379
DESCRIPTION- GRIFFITH et al., Annu. Rev. Immunol., (20140000), vol. 32, pages 659 - 702
DESCRIPTION- HANAHAN; FOLKMAN, Cell, (19960000), vol. 86, no. 3, pages 353 - 364
DESCRIPTION- HEMMI H et al., Nature, (20000000), vol. 408, pages 740 - 745
DESCRIPTION- Int J Nanomedicine, (20140000), vol. 9, pages 1833 - 1843
DESCRIPTION- J Cell Mol Med., (20130400), vol. 17, no. 4, pages 449 - 456
DESCRIPTION- KARLIN et al., PNAS USA, (19930000), vol. 90, pages 5873 - 5877
DESCRIPTION- KORE et al., Bioorg. Med. Chem., (20130000), vol. 21, no. 15, pages 4570 - 4575
DESCRIPTION- LAI et al., Development, (19950000), vol. 121, pages 2349 - 2360
DESCRIPTION- MEYLAN, E.; J. TSCHOPP et al., Nature, (20060000), vol. 442, no. 7098, pages 39 - 44
DESCRIPTION- MEYLAN, E.; TSCHOPP, J., "Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses", Mol. Cell, (20060000), vol. 22, pages 561 - 569
DESCRIPTION- MOOLTEN, Cancer Res., (19860000), vol. 46, no. 10, pages 5276 - 5281
DESCRIPTION- PERSANO et al., Mol. Aspects Med., (20070000), vol. 28, no. 1, pages 87 - 114
DESCRIPTION- STEPINSKI et al., RNA, (20010000), vol. 7, no. 10, pages 1486 - 1495
DESCRIPTION- WEBER, J., Semin. Oncol., (20100000), vol. 37, no. 5, pages 430 - 439
DESCRIPTION- WEINBERG et al., J. Immunother., (20060000), vol. 29, no. 6, pages 575 - 585
DESCRIPTION- WOO SR; CORRALES L; GAJEWSKI TF, "The STING pathway and the T cell-inflamed tumor microenvironment", Trends Immunol., (20150307), vol. 36, no. 4, pages 250 - 256
DESCRIPTION- PRENDERGAST GC; SMITH C; THOMAS S; MANDIK-NAYAK L; LAURY-KLEINTOP L; METZ R; MULLER AJ, "Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer", Cancer Immunol. Immunother, (20140700), vol. 63, no. 7, doi:doi:10.1007/s00262-014-1549-4, pages 721 - 735, XP055411380
DESCRIPTION- DUBENSKY TW JR; KANNE DB; LEONG ML, "Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants", Ther Adv Vaccines, (20131100), vol. 1, no. 4, doi:doi:10.1177/2051013613501988, pages 131 - 143, XP055177403
OPPOSITION- Anonymous, "Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1", Clinicaltrials.gov, (20150422), pages 1 - 9, Clinicaltrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT03721679, (20210115), XP055765557
OPPOSITION- B Ozpolat, Et Al, "Liposomal SIRNA Nanocarriers for Pre-published review article", ADVANCED DRUG DELIVERY REVIEWS, (20140101), vol. 66, pages 110 - 116, XP055715614
OPPOSITION- Daqing Wang, Et Al, "Abstract B196: Intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates tumor microenvironment and potentiates antitumor activity of anti-PD-1 mAb in a murine colon carcinoma model", (20151201), pages 1 - 5, XP055765515
OPPOSITION- Hatem Soliman, "Abstract 5018: Combination immunotherapy with PD-L1 blockade and Poly I:C in a murine breast cancer model", Proceedings of the 105th Annual Meeting of the - American Association for Cancer Research, (20141001), pages 1 - 4, XP055765531
OPPOSITION- Mangsbo Sara M et al, "Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy", Journal of Immunotherapy, Lippincott Williams & Wilkins, US, US, (20100401), vol. 33, no. 3, ISSN 1524-9557, pages 225 - 235, XP009144370
OPPOSITION- Primiano, Et Al, "Abstract 287: Specific Delivery of immunostimulatory RNA via under Article 54(2) EPC for all nanoparticles blocks growth of primary and claims not entitled to the priority disseminated ovarian tumors", Cancer Research, (20150801), pages 1 - 3, XP055715627
OPPOSITION- Shu Wang, Et Al, "Abstract 2322: Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade", Proceedings of the 107th Annual Meeting of the American - Association for Cancer Research, (20160701), pages 1 - 5, XP055765525
OPPOSITION- T Bald, Et Al, "Immune- cell poor Hgf-Cdk4 mouse melanomas benefit from anti- body mediated PD-1 blockade after targeted activation of the type I IFN system", Experimental Dermatology, (20150101), pages E32 - E33, XP055743302
OPPOSITION- HEIDENREICH REGINA ET AL, "A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile", International Journal of Cancer, John Wiley & Sons, Inc., US, US, (20150701), vol. 137, no. 2, doi:10.1002/ijc.29402, ISSN 0020-7136, pages 372 - 384, XP002776158
OPPOSITION- Fotin-Mleczek M et al, "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", The Journal of Gene Medicine, John Wiley & Sons, Inc, US, US, (20120601), vol. 14, no. 6, doi:10.1002/jgm.2605, ISSN 1099-498X, pages 428 - 439, XP002716014
OPPOSITION- AMOS et al., "Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice", Cancer Immunol Immunoth- er, (20151115), vol. 60, doi:10.1007/s00262-011-0984-8, pages 671 - 683, XP055285721
OPPOSITION- Sally M. Amos et al, "Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice", Cancer Immunology, Immunotherapy, Springer, Berlin/Heidelberg, Berlin/Heidelberg, (20110501), vol. 60, no. 5, doi:10.1007/s00262-011-0984-8, ISSN 0340-7004, pages 671 - 683, XP055285721
OPPOSITION- Hyun-Il Cho et al, "BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses", Cancer Immunology, Immunotherapy, Springer, Berlin/Heidelberg, Berlin/Heidelberg, (20130401), vol. 62, no. 4, doi:10.1007/s00262-012-1382-6, ISSN 0340-7004, pages 787 - 799, XP055478874
OPPOSITION- Klein Johanna C.; Wild Clarissa A.; Lang Stephan; Brandau Sven, "Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands", Cancer Immunology, Immunotherapy, Springer, Berlin/Heidelberg, Berlin/Heidelberg, (20160331), vol. 65, no. 6, doi:10.1007/s00262-016-1828-3, ISSN 0340-7004, pages 689 - 700, XP035693761
OPPOSITION- SALMON et al., "Expansion and Activation of CD 103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition", Immunity, (20160419), vol. 44, doi:10.1016/j.immuni.2016.03.012, pages 924 - 938, XP029521260
OPPOSITION- Salmon Hélène et al, "Expansion and Activation of CD103+Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL, (20160419), vol. 44, no. 4, doi:10.1016/j.immuni.2016.03.012, ISSN 1074-7613, pages 924 - 938, XP029521260
OPPOSITION- Pardoll Drew M., "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, Nature Pub. Group, London, London, (20120322), vol. 12, no. 4, doi:10.1038/nrc3239, ISSN 1474-175X, pages 252 - 264, XP037114946
OPPOSITION- Pardoll Drew M., "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, GB, (20120322), vol. 12, no. 4, doi:10.1038/nrc3239, ISSN 1474-175X, pages 252 - 264, XP037114946
OPPOSITION- Kevin Van Der Jeught, Sandra Van Lint, Kris Thielemans, Karine Breckpot, "Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy", OncoImmunology, (20150504), vol. 4, no. 5, doi:10.1080/2162402X.2015.1005504, page e1005504, XP055463808
OPPOSITION- VAN DER JEUGHT et al., "Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy", Oncolmmunology, (20150203), vol. 4, no. 5, doi:10.1080/2162402X.2015.1005504, page e1005504, XP055463808
OPPOSITION- Hyun-Il Cho et al, "An optimized peptide vaccine strategy capable of inducing multivalent CD8 + T cell responses with potent antitumor effects", OncoImmunology, (20151102), vol. 4, no. 11, doi:10.1080/2162402X.2015.1043504, page e1043504, XP055690374
OPPOSITION- Wilgenhof S et al, "A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.", Annals of Oncology, Oxford University Press, GB, GB, (20131001), vol. 24, no. 10, doi:10.1093/annonc/mdt245, ISSN 1569-8041, pages 2686 - 2693, XP009174113
OPPOSITION- Yanyan Lou et al, "Antitumor Activity Mediated by CpG : The Route of Administration is Critical", Journal of Immunotherapy, vol. 34, n. 3, doi:10.1097/CJI.0b013e31820d2a05, (20110401), pages 279 - 288, Journal of Immunotherapy, vol. 34, n. 3, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119202/pdf/nihms-268033.pdf, (20190415), XP055580785
OPPOSITION- Sacha Gnjatic, Et Al., "Toll-Like Receptor Agonists : Are They Good Adjuvants?", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, US, (20100701), vol. 16, no. 4, doi:10.1097/PPO.0b013e3181eaca65, ISSN 1528-9117, pages 382 - 391, XP055641509
OPPOSITION- A. Marabelle, H. Kohrt, C. Caux, R. Levy, "Intratumoral Immunization: A New Paradigm for Cancer Therapy", CLINICAL CANCER RESEARCH, American Association for Cancer Research, US, US, (20140401), vol. 20, no. 7, doi:10.1158/1078-0432.CCR-13-2116, ISSN 1078-0432, pages 1747 - 1756, XP055463812
OPPOSITION- MARABELLE et al., "Intratumoral Immunization: A New Paradigm for Cancer Thera- py", Clin. Cancer Res., (20140401), vol. 20, no. 7, doi:10.1158/1078-0432.CCR-13-2116, pages 1747 - 1756, XP055463812
OPPOSITION- NAGATO et al., "Combinatorial Immunotherapy of Polyinosinic-Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD 8 T- cell Re- sponses against Established Tumors", Clin Cancer Res, (20140103), vol. 20, no. 5, doi:10.1158/1078-0432.CCR-13-2781, pages 1223 - 34, XP055477177
OPPOSITION- Toshihiro Nagato, Young-Ran Lee, Yasuaki Harabuchi, Esteban Celis, "Combinatorial Immunotherapy of Polyinosinic-Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors", CLINICAL CANCER RESEARCH, American Association for Cancer Research, US, US, (20140301), vol. 20, no. 5, doi:10.1158/1078-0432.CCR-13-2781, ISSN 1078-0432, pages 1223 - 1234, XP055477177
OPPOSITION- T. Bald et al, "Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation", CANCER DISCOVERY, American Association for Cancer Research, US, US, (20140601), vol. 4, no. 6, doi:10.1158/2159-8290.CD-13-0458, ISSN 2159-8274, pages 674 - 687, XP055411718
OPPOSITION- T. Bald, Landsberg J., Lopez-Ramos D., Renn M., Glodde N., Jansen P., Gaffal E., Steitz J., Tolba R., Kalinke U., Limmer A., Jonsson G., Holzel M., Tuting T., "Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation", CANCER DISCOVERY, American Association for Cancer Research, US, US, (20140601), vol. 4, no. 6, doi:10.1158/2159-8290.CD-13-0458, ISSN 2159-8274, pages 674 - 687, XP055411718
OPPOSITION- A. R. Sanchez-Paulete et al, "Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells", CANCER DISCOVERY, American Association for Cancer Research, US, US, (20160101), vol. 6, no. 1, doi:10.1158/2159-8290.CD-15-0510, ISSN 2159-8274, pages 71 - 79, XP055427653
OPPOSITION- A. Salazar, Et Al, "Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial", Cancer Immunology Research, (20140101), vol. 2, no. 8, doi:10.1158/2326-6066.CIR-14-0024, pages 720 - 724, XP055715646
OPPOSITION- A. Salazar, Et Al, "Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial", Cancer Immunology Research, (20140101), vol. 2, no. 8, pages 720 - 724, XP055715646
OPPOSITION- José I. Quetglas, Sara Labiano, M. Ángela Aznar, Elixabet Bolaños, Arantza Azpilikueta, Inmaculada Rodriguez, Erkuden Casales, Alfonso R. Sánchez-Paulete, Víctor Segura, Cristian Smerdou, Ignacio Melero, "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade", CANCER IMMUNOLOGY RESEARCH, American Association for Cancer Research, US, US, (20150501), vol. 3, no. 5, doi:10.1158/2326-6066.CIR-14-0216, ISSN 2326-6066, pages 449 - 454, XP055576398
OPPOSITION- QUETGLAS et al., "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL 12 Synergizes with PD-1/PD-L1 Blockade", Cancer Immunol Res., (20150217), vol. 3, no. 5, doi:10.1158/2326-6066.CIR-14-0216, pages 449 - 54, XP055576398
OPPOSITION- Alicia Rodriguez-Gascon, Ana Del Pozo-Rodr�guez, Mar�a Angeles Solin�s, "Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles", International Journal of Nanomedicine, DOVE Medical Press, (20140401), doi:10.2147/IJN.S39810, ISSN 11769114, page 1833, XP055200967
OPPOSITION- XIAO et al., "Local Administration of TLR Ligands Rescues the Function of Tu- mor-Infiltrating CD 8 T Cells and Enhances the Antitumor Effect of Lentivector Immunization", J. Immunol., (20130422), vol. 190, doi:10.4049/jimmunol.1203470, pages 5866 - 5873, XP002739058
OPPOSITION- Xiao H et al, "Local Administration of TLR Ligands Rescues the Function of Tumor-Infiltrating CD8 T Cells and Enhances the Antitumor Effect of Lentivector Immunization", The Journal of Immunology, Williams & Wilkins Co., (20130601), vol. 190, no. 11, doi:10.4049/jimmunol.1203470, ISSN 0022-1767, pages 5866 - 5873, XP002739058
OPPOSITION- M. Singh et al, "Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation", The Journal of Immunology, Williams & Wilkins Co., (20141101), vol. 193, no. 9, doi:10.4049/jimmunol.1401160, ISSN 0022-1767, pages 4722 - 4731, XP055290072
OPPOSITION- Toshihiro Nagato, Esteban Celis, "A novel combinatorial cancer immunotherapy : poly-IC and blockade of the PD-1/PD-L1 pathway", OncoImmunology, (20140501), vol. 3, no. 5, doi:10.4161/onci.28440, page e28440, XP055433976
SEARCH- REGINA HEIDENREICH ET AL, "A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile : RNAdjuvant promotes anti-tumor responses of protein and peptide vaccines", INTERNATIONAL JOURNAL OF CANCER, US, (20141221), vol. 137, no. 2, doi:10.1002/ijc.29402, ISSN 0020-7136, pages 372 - 384, XP055462897 [X] 11-20 * abstract * * page 372, column l, paragraph 1 - page 383, column r, paragraph 3 * [Y] 1-20 [I] 1-20
SEARCH- FOTIN-MLECZEK M ET AL, "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 14, no. 6, doi:10.1002/JGM.2605, ISSN 1099-498X, (20120601), pages 428 - 439, (20120627), XP002716014 [Y] 1-20 * abstract * * page 428, paragraph 1 - page 437, column r, paragraph 2 *
SEARCH- SALLY M. AMOS ET AL, "Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, (20110501), vol. 60, no. 5, doi:10.1007/s00262-011-0984-8, ISSN 0340-7004, pages 671 - 683, XP055285721 [Y] 1-20 * abstract * * page 671, column r, paragraph 1 - page 681, column l, paragraph 3 *
SEARCH- KEVIN VAN DER JEUGHT ET AL, "Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy", ONCOIMMUNOLOGY, (20150203), vol. 4, no. 5, doi:10.1080/2162402X.2015.1005504, page e1005504, XP055463808 [Y] 1-20 * abstract * * page 1 - page 2 *
SEARCH- WILGENHOF S ET AL, "A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients", ANNALS OF ONCOLOGY, OXFORD UNIVERSITY PRESS, GB, (20131001), vol. 24, no. 10, ISSN 1569-8041, pages 2686 - 2693, XP009174113 [Y] 1-20 * abstract * * page 2686 - page 2693, column l, paragraph 4 *
SEARCH- A. MARABELLE ET AL, "Intratumoral Immunization: A New Paradigm for Cancer Therapy", CLINICAL CANCER RESEARCH, US, (20140331), vol. 20, no. 7, doi:10.1158/1078-0432.CCR-13-2116, ISSN 1078-0432, pages 1747 - 1756, XP055463812 [Y] 1-20 * abstract * * page 1747, column l, paragraph 1 - page 1754, column r, paragraph 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents